GAS6 and cholangiocarcinoma: Furthermore, we determined if sAxl and Gas6 are specific for HCC by comparison to patients with HCC-free liver disease with and without cirrhosis, and to healthy volunteers, as well as to cholangiocarcinoma (CCA), and to colorectal liver metastases (CRCLM) (n = 1111).